Simulect (Basiliximab)

What Is Simulect and What Is It Used For?

Simulect (basiliximab) is a monoclonal antibody used to prevent acute rejection of a transplanted kidney in adults and children. It is given as induction therapy around the time of transplantation, alongside cyclosporine and corticosteroids, and works by selectively blocking the T cells that would otherwise attack the donor kidney.

Simulect is classified pharmacologically as a selective immunosuppressant and belongs to the group of interleukin-2 receptor antagonists (IL-2 RA). Its active substance, basiliximab, is a chimeric (mouse-human) monoclonal antibody that was first approved by the European Medicines Agency and the U.S. Food and Drug Administration in 1998. It remains a cornerstone of modern induction immunosuppression protocols in kidney transplantation, used in tens of thousands of patients worldwide each year.

The approved indication is the prevention of acute organ rejection in de novo (first-time) allogeneic renal transplantation. In this context, basiliximab is administered as part of an immunosuppressive regimen that also includes cyclosporine for microemulsion and corticosteroids, and increasingly a fourth agent such as mycophenolate mofetil. Simulect is not approved for the treatment of rejection that has already begun, nor for solid-organ transplants other than kidney, although it is sometimes used off-label in liver and heart transplantation under specialist supervision.

Kidney transplantation is the treatment of choice for end-stage renal disease (ESRD) because it offers better quality of life and survival than long-term dialysis. However, the recipient's immune system naturally recognises the donor kidney as foreign tissue and attempts to destroy it. Without immunosuppression, acute rejection would occur in the vast majority of transplants within days to weeks. The role of Simulect is to dampen the specific T-cell response that drives this early rejection while preserving as much general immune function as possible.

How Simulect Works

Basiliximab binds with high affinity and specificity to the alpha chain (CD25) of the interleukin-2 (IL-2) receptor complex. This receptor is expressed at high density on the surface of activated T-lymphocytes — the very cells that orchestrate acute rejection — but not on resting T cells. By saturating CD25, basiliximab functions as a competitive antagonist of IL-2, the key growth factor that activated T cells need to proliferate and attack the graft.

Blockade of the IL-2 receptor is complete, sustained, and specific. Clinical pharmacology studies have shown that two standard doses of Simulect maintain CD25 saturation for approximately 4 to 6 weeks after transplantation — precisely the window during which acute rejection risk is highest. This targeted mechanism distinguishes Simulect from older, non-selective induction agents such as polyclonal antithymocyte globulin (ATG), which deplete all T cells and carry a higher risk of infection and lymphoproliferative complications.

The half-life of basiliximab is approximately 7 days in adults and 9 days in pediatric patients, and the drug is cleared primarily by endogenous catabolism rather than renal or hepatic metabolism. This is clinically important because no dose adjustment is required for impaired kidney or liver function. Once the drug has been cleared, CD25 expression returns to normal and the immune system regains full responsiveness to IL-2 signalling.

Clinical Efficacy

The efficacy of Simulect has been established in multiple randomized controlled trials and real-world registries. In the pivotal CHIB-201 and CHIB-202 trials, patients receiving basiliximab in addition to cyclosporine and corticosteroids experienced a significant reduction in biopsy-confirmed acute rejection at 6 and 12 months post-transplant compared with placebo. Pooled meta-analyses have shown an absolute risk reduction of 12 to 15 percent in the first-year rejection rate, without a significant increase in infection or malignancy rates.

Modern immunosuppression regimens build on these findings. According to the KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guidelines, IL-2 receptor antagonists such as basiliximab are recommended as the first-line induction agent in low-to-moderate immunological risk kidney transplant recipients, with T-cell-depleting agents reserved for higher-risk cases. This positions Simulect as a safer, more selective option for a large proportion of transplant candidates.

What Should You Know Before Taking Simulect?

Simulect must not be given to patients with known hypersensitivity to basiliximab, during pregnancy or breastfeeding, or outside a specialist transplant unit. Women of childbearing potential must use effective contraception during treatment and for 16 weeks after the final dose. Live vaccines should be avoided before and during immunosuppressive therapy.

Because Simulect is used at the critical moment of kidney transplantation, the pre-treatment evaluation is thorough and is normally carried out by the transplant team over several months. It includes detailed immunological, virological and cardiovascular assessments to confirm that the recipient is fit for surgery and for the combined immunosuppressive regimen. Understanding the contraindications, warnings and precautions associated with Simulect is essential both for patient safety and for informed consent.

Contraindications

You must not receive Simulect if any of the following apply:

• Hypersensitivity to basiliximab or to any of the other ingredients in the formulation (a full list is provided in the composition section below)
• Pregnancy — basiliximab is contraindicated during pregnancy because immunoglobulins cross the placenta and the drug could harm the developing fetus
• Breastfeeding — the drug may be excreted in breast milk and its effect on the nursing infant is unknown
• Severe, uncontrolled active infection that makes transplantation unsafe

If you believe any of these apply to you, discuss them with your transplant team well before surgery is planned.

Warnings and Precautions

Simulect may only be administered by healthcare professionals experienced in immunosuppressive therapy and in the care of organ transplant recipients, in a setting where full resuscitation equipment is immediately available. Specific warnings to consider include:

• Severe acute hypersensitivity reactions: Anaphylaxis has been reported, most often within the first 24 hours of administration. Symptoms include rash, urticaria (hives), pruritus, sneezing, wheezing, hypotension, tachycardia, respiratory failure, angioedema (swelling of face, lips or tongue), and capillary leak syndrome
• Cytokine release syndrome: A systemic inflammatory response characterised by fever, chills, hypotension and multi-organ dysfunction, distinct from the typical hypersensitivity pattern
• Severe infections: As with any immunosuppressive therapy, combined regimens increase the risk of opportunistic infections (including cytomegalovirus, BK polyomavirus, Pneumocystis jirovecii, Epstein-Barr virus and invasive fungal infections)
• Post-transplant lymphoproliferative disorder (PTLD): A rare but serious complication of immunosuppression, more common in Epstein-Barr virus-naive recipients (particularly children)
• Immunogenicity: Re-exposure to basiliximab after a previous course is possible but requires extra vigilance for hypersensitivity reactions
• Impact on infections and malignancies: Signs of infection (fever, persistent cough, painful urination, unusual bruising) or of new lumps in the skin or lymph nodes should be reported to the transplant team without delay

Tests and Monitoring

Before you receive Simulect and during the post-transplant period, the transplant team will perform or arrange a range of tests, including:

• HLA typing and cross-matching of donor and recipient to assess immunological risk
• Serological testing for cytomegalovirus (CMV), Epstein-Barr virus (EBV), hepatitis B, hepatitis C and HIV
• Chest imaging and dental assessment to rule out hidden sources of infection
• Baseline kidney function, liver enzymes, lipids, glucose and complete blood count
• Cardiovascular risk assessment, given the frequent coexistence of diabetes, hypertension and coronary disease in ESRD patients

After the transplant, you will be seen very frequently during the first weeks — sometimes every other day — so that blood counts, creatinine, calcineurin-inhibitor levels, and early signs of infection or rejection can be monitored closely.

Pregnancy and Breastfeeding

Simulect is classified as contraindicated during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 16 weeks after the last dose of Simulect (corresponding to more than four times the drug's half-life).

• A pregnancy test is performed before treatment begins and should be negative
• Basiliximab, like other immunoglobulins, may cross the placenta and affect the developing immune system of the fetus
• Basiliximab may also be excreted in breast milk; breastfeeding is therefore contraindicated during treatment and for 16 weeks afterwards
• If you become pregnant or suspect pregnancy after receiving Simulect, contact the transplant team immediately so that the wider immunosuppressive regimen can be reassessed

Driving and Operating Machinery

No specific effects of Simulect itself on the ability to drive or use machines have been observed. However, the peri-operative period involves general anaesthesia, sedative medications, and significant fatigue, so patients should not drive until the full transplant team confirms that it is safe to do so.

Children and Adolescents

Simulect is approved for use in children and adolescents (1 to 17 years of age) undergoing kidney transplantation, using a body-weight-adjusted dose. Safety and efficacy have been demonstrated in pediatric trials, although the long-term risk of post-transplant lymphoproliferative disorder is somewhat higher in EBV-naive children. Use in infants under 1 year of age is not established.

How Does Simulect Interact with Other Drugs?

Simulect is designed to be combined with cyclosporine, corticosteroids and mycophenolate mofetil without dose adjustment. It can be used safely with most medications but requires caution with other monoclonal antibodies, T-cell-depleting agents and live vaccines. There are no clinically significant cytochrome P450-based interactions because basiliximab is a protein, not a small molecule.

Unlike most small-molecule immunosuppressants, basiliximab is a large protein that is cleared by the body's general mechanisms for breaking down immunoglobulins. It does not interact with the cytochrome P450 enzyme system or with transporter proteins such as P-glycoprotein. As a result, the interaction profile is driven almost entirely by additive effects on the immune system, not by altered drug metabolism. Inform the transplant team about every medicine, supplement or herbal product you take, including over-the-counter agents.

Major Interactions

Minor Interactions and Practical Considerations

Drugs that do not directly interact with basiliximab but that are commonly used alongside it include antibacterial prophylaxis (such as trimethoprim-sulfamethoxazole), antiviral prophylaxis (such as valganciclovir for CMV), proton pump inhibitors, and cardiovascular medications for hypertension or dyslipidaemia. These generally do not require dose adjustment because of Simulect itself, although they may interact with concurrent calcineurin inhibitors and should be reviewed by the transplant pharmacist.

Food, alcohol and herbal supplements do not directly affect basiliximab pharmacokinetics. However, St John's wort, grapefruit juice and some high-dose herbal preparations can significantly alter cyclosporine and tacrolimus levels and should be avoided. Always check new supplements with the transplant team before starting them.

What Is the Correct Dosage of Simulect?

The standard adult dose of Simulect is 20 mg given intravenously within 2 hours before the kidney transplant and a second 20 mg dose 4 days after transplantation. The pediatric dose is weight-based: 10 mg for children weighing less than 35 kg and 20 mg for those weighing 35 kg or more. Each dose is administered as a bolus or a 20- to 30-minute infusion.

Simulect is not a take-home medicine. It is prepared by the hospital pharmacy and administered by nursing staff exclusively in the transplant unit or post-operative care area. Because the total course consists of only two doses, the concepts of "missed dose" or "overdose" work quite differently than with daily oral medications — missed doses are rare but clinically important, and overdose has only been documented in rare, carefully managed circumstances.

Adults

Children and Adolescents

Elderly Patients

Renal and Hepatic Impairment

How Simulect Is Given

Simulect is reconstituted with sterile water for injections to form a clear, colourless solution. It can then be further diluted in sodium chloride 0.9% or glucose 50 mg/mL (5%) solution. The final preparation is administered in one of two ways:

• Bolus intravenous injection: given directly into a vein over several minutes
• Short intravenous infusion: given over 20 to 30 minutes through a dedicated infusion line

The reconstituted product should ideally be used immediately but may be stored refrigerated (2 to 8°C) for up to 24 hours or at room temperature (below 25°C) for up to 4 hours, after which any unused portion must be discarded. Simulect must not be mixed in the same infusion line with other medicines.

Missed or Delayed Dose

If the second dose cannot be given on post-operative day 4 — for example, because of graft rejection detected very early, unexpected allergic reaction to the first dose, or surgical complications — the transplant team will reassess the risk-benefit balance. In most cases of allergic reaction, the second dose is withheld. In other scenarios, the second dose is usually given within a narrow window as close to day 4 as possible.

Overdose

Doses of up to 60 mg as a single injection have been given to humans in clinical studies without acute adverse effects. No specific antidote exists. In the event of overdose, the patient should be observed closely for signs of hypersensitivity, cytokine release and over-immunosuppression, and symptomatic and supportive treatment should be initiated if needed.

What Are the Side Effects of Simulect?

The most common side effects reported with Simulect include constipation, urinary tract infections, pain, nausea, peripheral edema, hypertension, anemia, headache, hyperkalemia, hypercholesterolemia, and surgical wound complications. Severe hypersensitivity reactions and cytokine release syndrome are uncommon but potentially life-threatening. Most side effects occur in the context of combined immunosuppressive therapy rather than being specific to basiliximab alone.

Like all medicines, Simulect can cause side effects, but not everyone will experience them. The frequencies listed below combine data from randomized clinical trials and post-marketing surveillance in adult and pediatric kidney transplant recipients. Because Simulect is always used together with other immunosuppressants, it can be difficult to attribute individual adverse events to basiliximab specifically; many reflect the underlying disease, the transplant surgery, or the combined drug regimen.

Reported Side Effects by Frequency

Hypersensitivity Reactions Explained

Severe hypersensitivity reactions to Simulect usually occur within 24 hours of administration but can also appear on a second exposure months later. The clinical picture ranges from mild rash or itching to full anaphylaxis with cardiovascular collapse, bronchospasm and angioedema. Some reactions overlap with capillary leak syndrome, a condition in which fluid and proteins leak from blood vessels into surrounding tissues, causing hypotension, hemoconcentration and tissue edema.

Because Simulect is a chimeric (partly murine) antibody, patients can develop antibodies against basiliximab itself, which may contribute to allergic-type reactions on re-exposure. Treatment centers are trained to recognise hypersensitivity early and to respond with adrenaline (epinephrine), intravenous fluids, antihistamines and corticosteroids as needed. Patients who have experienced a severe reaction should not receive Simulect again.

Managing and Reporting Side Effects

Because Simulect is given in hospital, most early side effects are identified by the clinical team directly. After discharge, patients play a crucial role in reporting new symptoms: fever or flu-like illness, painful urination, new skin lumps or rashes, unusual bruising, persistent cough, or marked changes in urine output should all be reported without delay. Many national medicines agencies also encourage patients and healthcare professionals to report suspected adverse reactions through their official pharmacovigilance systems.

How Should You Store Simulect?

Simulect is stored and handled exclusively by hospital staff. Unopened vials are kept in a refrigerator at 2 to 8°C and must not be frozen. Reconstituted solution should be used immediately or stored at 2 to 8°C for up to 24 hours or at room temperature (below 25°C) for up to 4 hours.

As a patient, you will not be responsible for storing Simulect at home. The product is handled exclusively by trained healthcare professionals in the hospital pharmacy and on the transplant ward. However, understanding the storage requirements helps illustrate the precision needed to preserve the antibody's activity.

Unopened vials of Simulect must be stored in a refrigerator at 2 to 8°C in their original outer packaging to protect them from light. The product must not be frozen, because freezing can damage the antibody structure. Each vial is labelled with an expiry date that must not be exceeded. Simulect vials that have been allowed to come to room temperature may be returned to refrigerated storage if this is documented, but repeated temperature cycling should be avoided.

Once reconstituted, the clear, colourless solution should ideally be used immediately. If not used immediately, the solution may be stored at 2 to 8°C for up to 24 hours, or at room temperature (below 25°C) for up to 4 hours. Any unused solution after these periods must be discarded in accordance with local biohazard procedures. Discoloured, cloudy or visibly particulate solutions must not be used.

What Does Simulect Contain?

Each vial of Simulect contains basiliximab as the active ingredient (10 mg or 20 mg), plus monohydrate potassium dihydrogen phosphate, disodium hydrogen phosphate (anhydrous), sodium chloride, sucrose, mannitol, and glycine. The solvent supplied is water for injections.

The active ingredient in Simulect is basiliximab, a chimeric murine/human monoclonal IgG1 kappa antibody produced by recombinant DNA technology in an established mouse myeloma cell line. Two vial strengths are available:

• Simulect 10 mg: each vial contains 10 mg basiliximab as a powder for reconstitution, supplied with 2.5 mL water for injections in a separate ampoule
• Simulect 20 mg: each vial contains 20 mg basiliximab as a powder for reconstitution, supplied with 5 mL water for injections in a separate ampoule

After reconstitution, each vial contains 4 mg basiliximab per mL.

Excipients (Inactive Ingredients)

The powder contains the following inactive ingredients:

• Monohydrate potassium dihydrogen phosphate
• Disodium hydrogen phosphate (anhydrous)
• Sodium chloride
• Sucrose
• Mannitol
• Glycine

The solvent is water for injections. Simulect does not contain preservatives, colouring agents or human-derived excipients, which simplifies its safety profile in patients with multiple allergies.

Appearance and Packaging

Simulect powder is a white lyophilized cake in a clear glass vial sealed with a rubber stopper and aluminium flip-off cap. The accompanying solvent (water for injections) is supplied in a clear glass ampoule. After reconstitution, the solution is clear and colourless to pale yellow, and should be visually inspected for particles or discoloration before use. Simulect is usually supplied as a combination pack containing one powder vial and one solvent ampoule.

Marketing Authorisation

Simulect has been centrally authorised in the European Union since 9 October 1998 and in the United States since 12 May 1998. The marketing authorisation holder in the EU is Novartis Europharm Limited. Detailed product information, including the most up-to-date Summary of Product Characteristics, is available from the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA) and national medicines agencies.